RT Journal
A1 Hansen M, Gislason G, Torp-Pedersen C
T1 DUal antiplatelet therapy and the risk of bleeding—reply
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2011
FD April 25
VO 171
IS 8
SP 782
OP 790
DO 10.1001/archinternmed.2011.148
UL http://dx.doi.org/10.1001/archinternmed.2011.148
AB 
First, dual aspirin and clopidogrel should not be a treatment regime on patients who do not receive OAC therapy due to bleeding risk. The bleeding risk with dual aspirin and clopidogrel therapy is at best comparable to what is seen with OAC therapy. This was shown in the ACTIVE W trial, which also taught us that to obtain protection against stroke, you need OAC therapy.2